|
 DexCom, Inc. (Nasdaq:DXCM)
Shares of DXCM surged $5.99 (or +21.99%) to $33.23 on Thursday's market activity after the company reported its financial results. DXCM also was upgraded from Under Perform to Market Perform by brokerage firm Northland Capital. For the third quarter of 2013, DXCM posted total revenue of $42.9 million, an 86% increase year over year, and product gross profit of $27.7 million compared to $7.7 million in the same period the prior year. DXCM reported a net loss of $6.0 million, or $0.08 per share for the period, compared to a net loss of $17.3 million, or $0.25 per share for the three months ended September 30, 2012. The net loss of $6.0 million included $9.5 million in non-cash expenses, comprised primarily of share-based compensation, depreciation, and amortization. According to FactSet, analysts expected DXCM to take a loss of $0.13 per share on $35.8 million in revenue. DXCM expects to exceed its forecast of $140 million in revenue this year, and it ultimately expects revenue to grow at an annual rate of about 40%. 
DXCM is developing and marketing continuous glucose monitoring systems for ambulatory use by people with diabetes and by healthcare providers in the hospital. More about DexCom, Inc. (Nasdaq:DXCM) at www.dexcom.com **  Celldex Therapeutics, Inc. (Nasdaq:CLDX)
CLDX stock climbed $3.26 (or +15.16%) to $24.77, after the company reported positive data from its ongoing Phase 1 dose-escalation study of the fully human monoclonal antibody CDX-1127. The results suggest an excellent safety profile and demonstrate clear biologic activity and promising signs of clinical activity in an advanced, refractory patient population. No maximum tolerated dose has been reached to date. According to CLDX, CDX-1127 could play an important role in the field of cancer immunotherapy, an agonist with this safety and biologic activity profile has potential, particularly in combination with checkpoint inhibitors, where the ability to mount an immune response could expand the effectiveness of these compounds for more patients. CDX-1127 is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses, and may result in less toxicities due to its restricted expression and regulation. CDX-1127 is a potent anti-CD27 agonist that induces activation and proliferation of human T cells when combined with T-cell receptor stimulation. In lymphoid malignancies that express CD27 at high levels, CDX-1127 has an additional mechanism through a direct anti-tumor effect. 
CLDX is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. CLDX's pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. More about Celldex Therapeutics, Inc. (Nasdaq:CLDX) at www.celldex.com. **  The St. Joe Company (NYSE:JOE)
Shares of JOE jumped $2.86 (or +15.77%) to $20.99, after the company announced a sales agreement with AgReserves, Inc., a Utah corporation, to sell approximately 382,834 acres of its non-strategic timberland and rural land in Northwest Florida for $565 million. The final price is subject to an adjustment set forth in the Sales Agreement. This proposed transaction does not include land within JOEâ??s existing residential or commercial real estate segments or its resorts, leisure or leasing segment, nor include any land for which JOE had plans to develop or use in these types of operations in the foreseeable future. According to JOE, the proceeds from the sale will provide the Company with significant liquidity and numerous opportunities to create long-term value for its shareholders. 
JOE is a Florida-based real estate developer and manager. JOE owns land concentrated primarily in Northwest Florida and has significant residential and commercial land-use entitlements in hand or in process. The Company also owns various commercial, resort and club properties. More about The St. Joe Company (NYSE:JOE) at www.joe.com. ** Read full disclaimer at www.mikezaman.com/disclaimer
Related Articles -
Mike Zaman website, DexCom, Nasdaq:DXCM, DXCM, Celldex, Nasdaq:CLDX, CLDX, St Joe Co, NYSE:JOE, Celldex, Nasdaq:CLDX, CLDX, CDX-1127, cancer immunothe,
| 
